BR112022022980A2 - Uso de inibidores de fator d de complemento sozinhos ou em combinação com anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna - Google Patents

Uso de inibidores de fator d de complemento sozinhos ou em combinação com anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna

Info

Publication number
BR112022022980A2
BR112022022980A2 BR112022022980A BR112022022980A BR112022022980A2 BR 112022022980 A2 BR112022022980 A2 BR 112022022980A2 BR 112022022980 A BR112022022980 A BR 112022022980A BR 112022022980 A BR112022022980 A BR 112022022980A BR 112022022980 A2 BR112022022980 A2 BR 112022022980A2
Authority
BR
Brazil
Prior art keywords
combination
complement
nocturnal hemoglobinuria
paroxystic
antibodies
Prior art date
Application number
BR112022022980A
Other languages
English (en)
Inventor
Huang Mingjun
Hui James
Podos Steven
Patel Dharaben
Geffner Michael
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of BR112022022980A2 publication Critical patent/BR112022022980A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

USO DE INIBIDORES DE FATOR D DE COMPLEMENTO SOZINHOS OU EM COMBINAÇÃO COM ANTICORPOS ANTI-C5 PARA TRATAMENTO DE HEMOGLOBINÚRIA PAROXÍSTICA NOTURNA. Trata-se de métodos para tratar hemoglobinúria paroxística noturna em um indivíduo que exibiu anteriormente uma resposta inadequada a uma terapia com anticorpo anti-C5, administrando ao indivíduo uma quantidade terapeuticamente eficaz de um inibidor da via alternativa de complemento (por exemplo, aquele que inibe um alvo a montante do complemento 5 (C5), como Fator D ou complemento 3 (C3)). Também são fornecidos no presente documento métodos para tratar PNH em um indivíduo humano, que compreende administrar ao indivíduo um inibidor do fator D do complemento sozinho ou em combinação com um anticorpo anti-C5 ou fragmento de ligação a antígeno do mesmo. Em algumas modalidades, o paciente exibiu anteriormente uma resposta inadequada a uma terapia com anticorpo anti-C5.
BR112022022980A 2020-05-12 2021-05-11 Uso de inibidores de fator d de complemento sozinhos ou em combinação com anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna BR112022022980A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063023415P 2020-05-12 2020-05-12
US202063044431P 2020-06-26 2020-06-26
PCT/US2021/031832 WO2021231470A1 (en) 2020-05-12 2021-05-11 Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria

Publications (1)

Publication Number Publication Date
BR112022022980A2 true BR112022022980A2 (pt) 2022-12-20

Family

ID=76270068

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022980A BR112022022980A2 (pt) 2020-05-12 2021-05-11 Uso de inibidores de fator d de complemento sozinhos ou em combinação com anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna

Country Status (10)

Country Link
US (1) US20230172930A1 (pt)
EP (1) EP4149473A1 (pt)
JP (1) JP2023526051A (pt)
KR (1) KR20230009431A (pt)
CN (1) CN115666578A (pt)
AU (1) AU2021270867A1 (pt)
BR (1) BR112022022980A2 (pt)
CA (1) CA3178589A1 (pt)
MX (1) MX2022014275A (pt)
WO (1) WO2021231470A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120695186A (zh) * 2025-06-25 2025-09-26 辽宁省肿瘤医院 Cfd作为靶点在胃癌腹膜转移中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
WO1997033603A1 (en) 1996-03-13 1997-09-18 Trustees Of The University Of Pennsylvania Novel peptides which inhibit complement activation
US6653340B1 (en) 1997-06-03 2003-11-25 Biocryst Pharmaceuticals, Inc. Compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
PT1549333E (pt) 2002-09-20 2012-01-03 Univ Pennsylvania Análogos de compstatina com actividade melhorada
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
ES2390828T3 (es) 2005-11-28 2012-11-16 The Trustees Of The University Of Pennsylvania Análogos potentes de la compstatina
PL3167888T3 (pl) 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
US20110046075A1 (en) 2007-02-07 2011-02-24 Lambris John D Secreted Staphylococcus Aureus Proteins And Peptides For Use In Inhibiting Activation Of The Complement System
US20080269318A1 (en) 2007-04-30 2008-10-30 Carmelo Romano Treatment of age-related macular degeneration using inhibitors of complement factor d
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
EP2661433B1 (en) 2011-01-04 2017-08-16 Novartis AG Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
CN103796667A (zh) 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
JP6273274B2 (ja) 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
WO2014002054A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
JP6214647B2 (ja) 2012-06-28 2017-10-18 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
ES2644700T3 (es) 2012-06-28 2017-11-30 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
EP2867222A1 (en) 2012-06-28 2015-05-06 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002059A1 (en) 2012-06-29 2014-01-03 Novartis Ag CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
WO2014005150A1 (en) 2012-06-29 2014-01-03 Novartis Ag Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
WO2014009833A2 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
WO2014099546A1 (en) 2012-12-19 2014-06-26 Promerus, Llc Process for the preparation of high purity norbornene alkanols and derivatives thereof
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US10213476B2 (en) 2014-03-17 2019-02-26 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved potency and pharmacokinetic properties
EP3137503A1 (en) 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
CN107207607B (zh) 2014-12-19 2021-05-04 中外制药株式会社 抗-c5抗体及使用方法
EP3359555B1 (en) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosing regimens
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
ES2984352T3 (es) 2016-06-14 2024-10-29 Regeneron Pharma Anticuerpos anti-C5 y usos de los mismos
EP3580241A4 (en) 2017-02-10 2021-01-06 The Trustees Of The University Of Pennsylvania ANTIFACTOR D ANTIBODIES AND USES THEREOF
KR20210104071A (ko) * 2018-12-17 2021-08-24 아칠리온 파르마세우티칼스 인코포레이티드 보체 매개 장애의 치료를 위한 표적 투약

Also Published As

Publication number Publication date
MX2022014275A (es) 2022-12-07
US20230172930A1 (en) 2023-06-08
EP4149473A1 (en) 2023-03-22
CN115666578A (zh) 2023-01-31
KR20230009431A (ko) 2023-01-17
WO2021231470A1 (en) 2021-11-18
AU2021270867A1 (en) 2022-12-08
CA3178589A1 (en) 2021-11-18
JP2023526051A (ja) 2023-06-20

Similar Documents

Publication Publication Date Title
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
BR112021021713A2 (pt) Método de tratamento de câncer ou inibição do crescimento de um tumor
BR112021018627A2 (pt) Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia
BR112022007595A2 (pt) Métodos para tratar doença de alzheimer
BR112022000231A2 (pt) Novos métodos
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
BR112014011144A2 (pt) tratamento de malignidades hematológicas com um anticorpo anti-cxcr4
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
CY1111478T1 (el) Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
CY1125948T1 (el) Σχημα αγωγης που χρησιμοποιει νερατινιμπη για τον καρκινο του μαστου
BR112017026189A2 (pt) tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
EA200970335A1 (ru) Композиции и способы для диагностики и лечения рака
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
UA94899C2 (ru) Фиксированное дозирование антител к her
AR068532A1 (es) Inhibicion de angiogenesis
GEAP202516662A (en) Anti-nectin-4 antibody, conjugate including same, and application thereof
BR112022022578A2 (pt) Novas composições e métodos de tratar doença covid-19
MX2022003668A (es) Metodos y composiciones para el tratamiento de la retinopatia diabetica.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
MX2021004207A (es) Uso de reboxetina para el tratamiento de narcolepsia.
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]